Summit Therapeutics Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Unaudited U.S. GAAP figures; financial amounts below are in millions unless stated otherwise.
Business context
Summit is a clinical-stage biopharmaceutical company. Its strategy has shifted from anti-infectives to oncology following its January 2023 license of ivonescimab (SMT112) from Akeso, for development and commercialization in the United States, Canada, Europe and Japan. The company is advancing two Phase III NSCLC trials: HARMONi and HARMONi-3. It is reviewing anti-infectives activities for potential partnerships.
Financial highlights
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0.220 | $0 | $0.705 |
| Research and development expense | $15.323 | $17.049 | $34.657 | $46.613 |
| In-process R&D expense | $0 | $0 | $520.915 | $0 |
| General and administrative expense | $5.434 | $5.573 | $18.690 | $19.165 |
| Net loss | $21.268 | $21.385 | $578.361 | $59.553 |
| Operating cash used | — | $57.301 | $46.773 |
The nine-month in-process R&D charge records the Akeso license consideration as an expense: $474.9 million cash, 10 million shares valued at $45.9 million, and transaction costs. The reported nine-month loss and loss per share ($0.98, versus $0.37 in 2022) therefore include this substantial one-time charge. Q3 loss per share was $0.03 versus $0.10.
At September 30, 2023, cash and cash equivalents were $23.792 million and short-term U.S. Treasury investments were $175.153 million. Current assets were $204.951 million; current liabilities were $113.742 million. Total liabilities were $119.097 million, including a $100 million related-party note classified as current. Accumulated deficit was $956.691 million. Common shares outstanding were 697.9 million at quarter-end and 700.8 million as of October 31, 2023.
Changes and management commentary
- Revenue ceased in 2023: prior-year revenue came from the Eurofarma ridinilazole agreement, whose performance period ended in 2022.
- Nine-month R&D expense fell by about $12.0 million year over year as anti-infectives spending declined, partly offset by $16.7 million of oncology R&D investment. Management expects oncology R&D costs to rise as ivonescimab development advances.
- The $520.9 million Akeso charge drove the increase in nine-month operating expenses and net loss. The license also provides for potential regulatory and commercial milestone payments of up to $4.5 billion and low double-digit royalties on net sales; amounts and timing are contingent and not estimable in the filing.
- The 2023 rights offering raised $500 million gross through 476.2 million shares at $1.05 per share. A portion of the proceeds was used to extinguish $395.3 million owed to Co-CEO Robert Duggan; the transaction significantly increased the share count.
- Management reported Phase III HARMONi enrollment underway and HARMONi-3 enrollment recently commenced. The filing also cites Phase II data for ivonescimab plus chemotherapy in a squamous NSCLC cohort: median progression-free survival of 11.0 months, response rate of 67%, and Grade 3 or higher treatment-related adverse events in 41%. These are interim study results, not Phase III outcomes.
Liquidity, outlook and risks
Summit states that it expects continuing operating losses and needs additional capital until it can generate substantial revenue and achieve profitability. A $100 million note payable to a related party matures September 6, 2024; management intends to raise capital to repay it, but had not secured that additional capital as of the filing. The company says its resources support planned operations into September 2024, while also concluding that substantial doubt exists about its ability to continue as a going concern for at least one year from issuance of the financial statements.
Potential funding sources include equity or debt offerings, collaborations, alliances, grants and licensing arrangements; availability and terms are uncertain. Failure to obtain funding could delay, reduce or eliminate development or commercialization plans and may dilute shareholders or require Summit to relinquish rights. Akeso milestone, royalty, manufacturing and supply obligations are additional potential cash needs. The company reported approximately $6.4 million of non-cancellable clinical-trial purchase commitments. It reported no material legal proceedings. Management assessed disclosure controls as effective at a reasonable level of assurance.
Important facts for investors to verify
- Progress, enrollment, timing and results of HARMONi and HARMONi-3, including the distinction between interim Phase II data and Phase III evidence.
- Whether Summit secures sufficient financing to fund operations and repay the $100 million related-party note by its September 2024 maturity.
- Cash use and remaining liquidity, including how clinical development spending and potential Akeso payments affect the runway.
- Potential dilution from future financing, outstanding equity awards, and the material increase in shares following the rights offering.
- Akeso license terms, including milestone triggers, royalties, and supply commitments, as these obligations may be significant but are not currently estimable.